Lantern Pharma Inc.
NASDAQ:LTRN
Income Statement
Earnings Waterfall
Lantern Pharma Inc.
Income Statement
Lantern Pharma Inc.
| Jun-2020 | Sep-2020 | Dec-2020 | Mar-2021 | Jun-2021 | Sep-2021 | Dec-2021 | Mar-2022 | Jun-2022 | Sep-2022 | Dec-2022 | Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | |||||||||||||||||||||||
| Revenue |
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
0
N/A
|
|
| Operating Income | |||||||||||||||||||||||
| Operating Expenses |
(1)
|
(3)
|
(6)
|
(8)
|
(10)
|
(12)
|
(13)
|
(14)
|
(16)
|
(14)
|
(14)
|
(15)
|
(15)
|
(17)
|
(18)
|
(19)
|
(20)
|
(21)
|
(22)
|
(21)
|
(21)
|
(20)
|
|
| Selling, General & Administrative |
(1)
|
(2)
|
(4)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(5)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(6)
|
(7)
|
|
| Research & Development |
(0)
|
(1)
|
(2)
|
(3)
|
(4)
|
(7)
|
(8)
|
(9)
|
(11)
|
(9)
|
(9)
|
(8)
|
(9)
|
(11)
|
(12)
|
(14)
|
(14)
|
(15)
|
(16)
|
(15)
|
(14)
|
(13)
|
|
| Operating Income |
(1)
N/A
|
(3)
-130%
|
(6)
-96%
|
(8)
-33%
|
(10)
-21%
|
(12)
-25%
|
(13)
-6%
|
(14)
-12%
|
(16)
-14%
|
(14)
+12%
|
(14)
-2%
|
(15)
-2%
|
(15)
-5%
|
(17)
-9%
|
(18)
-6%
|
(19)
-8%
|
(20)
-1%
|
(21)
-8%
|
(22)
-5%
|
(21)
+4%
|
(21)
+4%
|
(20)
+4%
|
|
| Pre-Tax Income | |||||||||||||||||||||||
| Interest Income Expense |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
|
| Non-Reccuring Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Other Income |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
(0)
|
0
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
|
| Pre-Tax Income |
(1)
N/A
|
(3)
-130%
|
(6)
-96%
|
(8)
-33%
|
(9)
-19%
|
(12)
-25%
|
(12)
-5%
|
(14)
-14%
|
(16)
-15%
|
(14)
+11%
|
(14)
+1%
|
(14)
+2%
|
(14)
-2%
|
(15)
-6%
|
(16)
-5%
|
(18)
-10%
|
(18)
-1%
|
(19)
-8%
|
(21)
-9%
|
(20)
+4%
|
(19)
+3%
|
(19)
+2%
|
|
| Net Income | |||||||||||||||||||||||
| Income from Continuing Operations |
(1)
|
(3)
|
(6)
|
(8)
|
(9)
|
(12)
|
(12)
|
(14)
|
(16)
|
(14)
|
(14)
|
(14)
|
(14)
|
(15)
|
(16)
|
(18)
|
(18)
|
(19)
|
(21)
|
(20)
|
(19)
|
(19)
|
|
| Net Income (Common) |
(1)
N/A
|
(3)
-130%
|
(6)
-96%
|
(8)
-33%
|
(9)
-19%
|
(12)
-25%
|
(12)
-5%
|
(14)
-14%
|
(16)
-15%
|
(14)
+11%
|
(14)
+1%
|
(14)
+2%
|
(14)
-2%
|
(15)
-6%
|
(16)
-5%
|
(18)
-10%
|
(18)
-1%
|
(19)
-8%
|
(21)
-9%
|
(20)
+4%
|
(19)
+3%
|
(19)
+2%
|
|
| EPS (Diluted) |
-0.21
N/A
|
-0.48
-129%
|
-0.95
-98%
|
-0.78
+18%
|
-0.83
-6%
|
-1.04
-25%
|
-1.13
-9%
|
-1.27
-12%
|
-1.49
-17%
|
-1.32
+11%
|
-1.31
+1%
|
-1.29
+2%
|
-1.32
-2%
|
-1.4
-6%
|
-1.47
-5%
|
-1.62
-10%
|
-1.65
-2%
|
-1.77
-7%
|
-1.93
-9%
|
-1.85
+4%
|
-1.79
+3%
|
-1.75
+2%
|
|